|
|
Post by mnholdem on Apr 28, 2020 6:42:34 GMT -5
You cannot blame Castagna for taking advantage of a loophole, especially if he thought it to be “free money”.
I find it a bit unethical, albeit legal, and advocate that MannKind’s CEO return the PPP money immediately for use with small businesses that have no options of securing loans/cash to pay their workers.
|
|
|
|
Post by mnholdem on Apr 28, 2020 6:37:33 GMT -5
Note: The MannKind-AMSL partnership was signed one month after evaluating commenced for Fiasp insulin (Novo Nordisk). My point is that, based upon the average timeline of Australia authorities to render drug approval decisions, MannKind stockholders may hear news soon.
Of course, we do not know the date of registration of Afrezza by AMSL. Was Afrezza registered immediately or was it delayed. I would think that CEO Castagna knows the answer.
Is this privileged information that cannot be shared with stockholders?
|
|
|
|
Post by mnholdem on Apr 28, 2020 6:12:19 GMT -5
|
|
|
|
Post by mnholdem on Apr 27, 2020 15:19:19 GMT -5
223 public companies received so-called PPP loans. Just 13 public firms have said they would return the loans as of early Monday afternoon. "Some lesser-known health care and biotechnology companies are also returning their loans. Among them is Wave Life Sciences, which got $7.2 million weeks after disclosing hefty losses and telling investors it could be “many years” before it had any products ready to sell, the Associated Press reported last week."Source: nypost.com/2020/04/27/only-13-companies-have-said-they-will-return-coronavirus-loans/ |
|
|
|
Post by mnholdem on Apr 27, 2020 15:12:01 GMT -5
Thanks for the correction, buyitonsale. I think have a really good memory, only it's short.  |
|
|
|
Post by mnholdem on Apr 25, 2020 12:50:06 GMT -5
Mango, you compared market cap but not outstanding shares. NVAX has ~42.6M outstanding while MNKD has ~213M outstanding and, considering that stockholders have been asked to authorize another 180M shares...
Also, Joey’s spot on about comparing apples to oranges. Diabetes/insulin is a huge market that also is crowded with powerful companies. Novavax has gone after the flu market and the data from its Phase 3 suggests that NanoFlu could take the #1 spot for its seasonal flu vaccine.
Wall Street prices in future potential earnings. MannKind has had 5 years and yet hasn’t convinced the market of its potential.
|
|
|
|
Post by mnholdem on Apr 22, 2020 13:00:10 GMT -5
Let’s start a list of questions for the annual shareholder meeting..... 1.....Mike, “how soon before you need to use those shares?” I seem to recall that question addressed to Mike a couple years ago. If my memory is correct, he had a slide of various instruments the company was exploring for raising cash. The last bullet point on that slide was a public stock offering and Castagna emphasized that would be a least preferable/last resort option. MannKind's CEO knew during the conference call - although he played it down to investors and, some may argue, even made it sound like it may not happen at all - that the company's public offering would announced the very next day. Is there any reason to believe what CEO Castagna will be more forthcoming with investors this time?  |
|
|
|
Post by mnholdem on Apr 22, 2020 12:47:46 GMT -5
I don't know specifically how the PPP is set up for small- or micro-cap companies that are publicly traded, but the deal the government made with the airlines provides the US Treasury warrants to buy up common stock. I just read an article this morning stating that the US taxpayer may soon become the second largest shareholder in several airline stocks (behind Berkshire Hathaway).  |
|
|
|
Post by mnholdem on Apr 20, 2020 9:32:06 GMT -5
Casper that is just plain not true!! I have never deleted a post, I have never blocked anyone! Stop with the lies ..stop with the false statements. Right.... ProBoard members cannot delete posts by other members and staff can easily check security logs to prove that Sportsrancho’s comments are accurate. Also, the ProBoards-MNKD staff is quite circumspect about deleting any post. Those that are removed typically violate board rules and some are removed for being off-topic. Sportsrancho appears to be telling the truth so I’m wondering why Casper is questioning her integrity. |
|
|
|
Post by mnholdem on Apr 12, 2020 13:57:00 GMT -5
Besides, Amphastar has manufacturing sites in other countries besides China. The fact that they built a plant in China was to gain admittance to China, a country will huge numbers but which also insists that corporations who want to do business in China must build in China.
|
|
|
|
Post by mnholdem on Apr 8, 2020 20:22:04 GMT -5
Correct. The Immix-MannKind collaboration has nothing in human trials. Pre-clinical work must come first before scheduling with the FDA... unless, that is, they are planning an API-device combo where both the drug and device (Dreamboat) are both already approved by the FDA. That would significantly shorten the timeline to Phase 2/3 trial. There is still the issue of who pays for the trial.
|
|
|
|
Post by mnholdem on Apr 8, 2020 14:59:51 GMT -5
clinicaltrials.gov/ct2/show/NCT03382340?term=Immix&draw=2&rank=1IMX-110 in Patients With Advanced Solid TumorsStudy Description Brief Summary: Phase 1 is an open-label, multi-center dose escalation/dose expansion study designed to assess the safety, tolerability and pharmacokinetics (PK) for the recommended phase 2 dose (RP2D) of IMX-110. The RP2D will be evaluated in a further dose expansion Phase 2a study submitted.
|
|
|
|
Post by mnholdem on Apr 7, 2020 5:54:05 GMT -5
Indeed!
|
|
|
|
Post by mnholdem on Apr 6, 2020 16:07:37 GMT -5
OMG! ...and what a family! It's almost like you have your own clinic at home. Thank God you pulled through this.  |
|
|
|
Post by mnholdem on Apr 2, 2020 11:29:31 GMT -5
On top of this, Cantor Fitzgerald’s Brandon Folkes notes, “MNKD continues to have excess manufacturing capacity which it can leverage to assist other companies in meeting any increased demand due to the outbreak.” MNKD has excess manufacturing capacity it can use for other than Afrezza and treprostinil? Where? Is it possible to have other drugs produced on the two production lines while still producing Afrezza and treprostinil? Unless memory fails, former CEO/CFO Matthew Pfeffer had built out 3 finish-fill lines, not 2 lines, with the final line having a considerably higher capacity and/or production rate than the first line, which was completed many years ago at the Danbury CT facility. |
|
